99 related articles for article (PubMed ID: 7749309)
1. Hypocholesterolemic agents.
Endo A
Biotechnology; 1994; 26():301-20. PubMed ID: 7749309
[No Abstract] [Full Text] [Related]
2. A gift from nature: the birth of the statins.
Endo A
Nat Med; 2008 Oct; 14(10):1050-2. PubMed ID: 18841147
[No Abstract] [Full Text] [Related]
3. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs.
Davis HR; Pula KK; Alton KB; Burrier RE; Watkins RW
Metabolism; 2001 Oct; 50(10):1234-41. PubMed ID: 11586500
[TBL] [Abstract][Full Text] [Related]
4. RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase.
Amin D; Rutledge RZ; Needle SN; Galczenski HF; Neuenschwander K; Scotese AC; Maguire MP; Bush RC; Hele DJ; Bilder GE; Perrone MH
J Pharmacol Exp Ther; 1997 May; 281(2):746-52. PubMed ID: 9152381
[TBL] [Abstract][Full Text] [Related]
5. Compactin-a review.
Chakravarti R; Sahai V
Appl Microbiol Biotechnol; 2004 Jun; 64(5):618-24. PubMed ID: 15034683
[TBL] [Abstract][Full Text] [Related]
6. Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. 1976.
Endo A; Kuroda M; Tanzawa K
Atheroscler Suppl; 2004 Oct; 5(3):39-42. PubMed ID: 15531273
[No Abstract] [Full Text] [Related]
7. Regulation of the last two enzymatic reactions in cholesterol biosynthesis in rats: effects of BM 15.766, cholesterol, cholic acid, lovastatin, and their combinations.
Honda A; Shefer S; Salen G; Xu G; Batta AK; Tint GS; Honda M; Chen TC; Holick MF
Hepatology; 1996 Aug; 24(2):435-9. PubMed ID: 8690416
[TBL] [Abstract][Full Text] [Related]
8. Effects of simvastatin, a cholesterol synthesis inhibitor, on phosphatidylcholine synthesis in HepG2 cells.
Yanagita T; Yamamoto K; Ishida S; Sonda K; Morito F; Saku K; Sakai T
Clin Ther; 1994; 16(2):200-8. PubMed ID: 8062316
[TBL] [Abstract][Full Text] [Related]
9. [Action of lovastatin--an inhibitor of cholesterol biosynthesis on bacterial bioluminescence].
Baranova NA; Krĕier VG; Egorov NS
Antibiot Khimioter; 1995 Aug; 40(8):12-6. PubMed ID: 8713431
[TBL] [Abstract][Full Text] [Related]
10. [Cardiovascular pharmacology (VIII). The role of HMG CoA reductase inhibitors in the current treatment of hyperlipidemias].
Carmena R
Rev Esp Cardiol; 1995 Jan; 48(1):59-65. PubMed ID: 7878284
[No Abstract] [Full Text] [Related]
11. Cholesterol content of the rat lens is lowered by administration of simvastatin, but not by pravastatin.
De Vries AC; Vermeer MA; Bredman JJ; Bär PR; Cohen LH
Exp Eye Res; 1993 Apr; 56(4):393-9. PubMed ID: 8500554
[TBL] [Abstract][Full Text] [Related]
12. The role of isoprenoids in vascular smooth muscle: potential benefits of statins unrelated to cholesterol lowering.
Hughes AD
J Hum Hypertens; 1996 Jun; 10(6):387-90. PubMed ID: 8872802
[TBL] [Abstract][Full Text] [Related]
13. Grapefruit juice-lovastatin interaction.
Bailey DG; Dresser GK
Clin Pharmacol Ther; 2000 Jun; 67(6):690. PubMed ID: 10872652
[No Abstract] [Full Text] [Related]
14. Effects of hypocholesterolaemic agents on the expression and activity of 3-hydroxy-3-methylglutaryl-CoA reductase in the fat body of the German cockroach.
Zapata R; Martín D; Piulachs MD; Bellés X
Arch Insect Biochem Physiol; 2002 Apr; 49(4):177-86. PubMed ID: 11921076
[TBL] [Abstract][Full Text] [Related]
15. Statin therapy in clinical practice: new developments.
Shepherd J
Curr Opin Lipidol; 1995 Oct; 6(5):254-5. PubMed ID: 8520846
[No Abstract] [Full Text] [Related]
16. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
Pappu AS; Bacon SP; Illingworth DR
J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170
[TBL] [Abstract][Full Text] [Related]
17. Lyso-PAF analogues and lysophosphatidylcholines from the marine sponge Spirastrella abata as inhibitors of cholesterol biosynthesis.
Shin BA; Kim YR; Lee IS; Sung CK; Hong J; Sim CJ; Im KS; Jung JH
J Nat Prod; 1999 Nov; 62(11):1554-7. PubMed ID: 10579872
[TBL] [Abstract][Full Text] [Related]
18. The beneficial effects of HMG-coenzyme A reductase inhibitor in the primary and secondary prevention of atherosclerosis in the coronaries.
Drown DJ
Prog Cardiovasc Nurs; 1996; 11(2):38-9. PubMed ID: 8718962
[No Abstract] [Full Text] [Related]
19. Regulation of early cholesterol biosynthesis in rat liver: effects of sterols, bile acids, lovastatin, and BM 15.766 on 3-hydroxy-3-methylglutaryl coenzyme A synthase and acetoacetyl coenzyme A thiolase activities.
Honda A; Salen G; Nguyen LB; Xu G; Tint GS; Batta AK; Shefer S
Hepatology; 1998 Jan; 27(1):154-9. PubMed ID: 9425931
[TBL] [Abstract][Full Text] [Related]
20. The discovery and development of HMG-CoA reductase inhibitors.
Endo A
J Lipid Res; 1992 Nov; 33(11):1569-82. PubMed ID: 1464741
[No Abstract] [Full Text] [Related]
[Next] [New Search]
